TP53 and breast carcinoma: Finally, we retrieved the TCGA patient tumor data from the cBioPortal platform to query the clinical frequency and relevance of the identified AURKB, ZAK, and TP53 status in breast cancer patients.30 Interestingly, we found that a higher expression of ZAK is associated with poor survival of breast cancer patients (log-rank test, p < 0.0001, n = 1105, Fig. 4d).